NICE overturns decision on blood cancer treatment elranatamab

Elranatamab is now recommended as a fourth-line treatment for relapsed and refractory multiple myeloma, according to updated guidance from the National Institute for Health and Care Excellence.
Syringes and medicine bottles on a blue background
Both teclistamab and elranatamab bring together T cells and myeloma cells to allow the T cells to recognise and destroy the tumour cells

Shutterstock.com

The National Institute for Health and Care Excellence (NICE) has overturned previous draft guidance on elranatamab (Elrexfio; Pfizer), removing restrictions on the use of the treatment for multiple myeloma, following an agreement with the manufacturer to make the drug available to the NHS at a discount.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated